You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
All the tests are authorized for use by CLIA-certified labs, while Visby's test may also be performed in a point-of-care setting.
Binx Health said the initial distribution of its platform will be to settings certified to perform moderate- or high-complexity diagnostic tests under CLIA.
In December, the firm was named a finalist in a $6 million Xprize competition to develop a rapid test for detecting SARS-CoV-2.
Using a Cas13-based method, researchers at UCSB detected eight asymptomatic cases, while a single discrepant case had low estimated viral load.
While the tests from Clinomics, UPenn, and Inno Diagnostics detect the SARS-CoV-2 virus, Princeton BioMeditech's test differentiates between SARS-CoV-2 and influenza.
In an SEC filing, the firm said it intends to use the IPO proceeds to support manufacturing and establish a sales and marketing team, among other activities.
The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.
The company has two COVID-19 tests: One, a moderate high-complexity test, received EUA in September, while the other is in clinical trials.
The University of Birmingham-developed method combines a method called EXPAR with a rapid upfront step to obviate reverse transcription.
The test, a version of the company's rapid SARS-CoV-2 assay, will be designed for both point-of-care and at-home use as an over-the-counter product.
MicroGem is developing a PCR-based SARS-CoV-2 saliva test designed to detect SARS-CoV-2 at the point-of-care with results in 15 minutes.
The firm is also developing an instrument-free molecular diagnostic assay technology for the home testing market.
Talis, a point-of-care test developer, said that the principal purpose for the offering is to obtain additional capital to support its operations, among other purposes.
The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.
The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and strep A.
The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.
The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.